Sao Paulo, Brazil: Daily administration of CBD oil extracts does not help patients with COVID in their recovery from the disease, according to data from randomized placebo-controlled clinical trials published in the journal Cannabis and Cannabinoid Research.
A team of Brazilian researchers affiliated with the National Institute of Science and Technology evaluated the effectiveness of using 300 mg of CBD versus placebo in 91 patients with mild to moderate COVID symptoms. Participants consumed CBD daily for a period of 14 days in addition to their standard care.
The researchers reported that “daily administration of 300 mg of CBD for 14 days to patients with a recent diagnosis of mild to moderate COVID-19 was safe, but did not alter the clinical course in the first 28 days of Tracking”. Specifically, the authors did not report differences in subjects’ viral load, anxiety, or depression levels, or in “complete resolution of typical COVID-19 symptoms.”
They concluded: “Further trials with patients with different levels of severity of COVID-19 and CBD doses are needed to confirm the absence of CBD effects in the clinical course of COVID-19 observed in our study.”
A separate clinical trial from the same research team evaluates whether CBD “could act as an effective preventative agent for chronic symptoms of post-COVID-19 syndrome.”
NORML has previously warned about the marketing of certain CBD products as potential agents for the treatment of COVID-19, citing the lack of human data demonstrating its effectiveness as an antiviral agent.
The full text of the study, “Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial,” appears in Cannabis and Cannabinoid Research.
Like this:
Loading …
Related
/https://specials-images.forbesimg.com/imageserve/61957898c54e3de896959296/0x0.jpg "Cannuka Luxe And Neiman Marcus Are Making Shoppable CTV Advertising A Reality")
